Vonoprazan/amoxicillin/clarithromycin
| Combination of | |
|---|---|
| Vonoprazan | Potassium-competitive acid blocker |
| Amoxicillin | Beta-lactam antibiotic |
| Clarithromycin | Macrolide antibiotic |
| Clinical data | |
| Trade names | Vonosap, Voquezna Triple Pak |
| License data | |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| KEGG | |
Vonoprazan/amoxicillin/clarithromycin, sold under the brand name Vonosap among others, is a co-packaged medication used for the treatment of Helicobacter pylori (H. pylori) infection.[1][4] It contains vonoprazan (as the fumarate), a potassium-competitive acid blocker; amoxicillin, a beta-lactam antibiotic; and clarithromycin, a macrolide antibiotic.[1][4]
It was approved for medical use in Japan in 2016,[3] and in the United States in May 2022.[1][2][5][6]
References
- ^ a b c d "Voquezna Dual Pak- vonoprazan fumarate and amoxicillin kit Voquezna Triple Pak- vonoprazan fumarate, amoxicillin and clarithromycin kit". DailyMed. 21 June 2022. Archived from the original on 3 July 2022. Retrieved 3 July 2022.
- ^ a b "Phathom Pharmaceuticals Announces FDA Approval of Voquezna Triple Pak (vonoprazan, amoxicillin, clarithromycin) and Voquezna Dual Pak (vonoprazan, amoxicillin) for the Treatment of H. pylori Infection in Adults" (Press release). Phathom Pharmaceuticals. 3 May 2022. Archived from the original on 10 May 2022. Retrieved 9 May 2022 – via GlobeNewswire.
- ^ a b "Vonosap pack 400, Vonosap pack 800 and Vonopion pack (triple-drug blister packs containing Takecab tablet) Now Available for Helicobacter pylori[*] Eradication in Japan". Takeda. 7 June 2016. Archived from the original on 10 May 2022. Retrieved 9 May 2022.
- ^ a b Deguchi H, Yamazaki H, Kamitani T, Yamamoto Y, Fukuhara S (July 2021). "Impact of Vonoprazan Triple-Drug Blister Packs on H. pylori Eradication Rates in Japan: Interrupted Time Series Analysis". Adv Ther. 38 (7): 3937–3947. doi:10.1007/s12325-021-01784-w. PMC 8280045. PMID 34091865.
- ^ "FDA NDA approval" (PDF). U.S. Food and Drug Administration (FDA). Archived (PDF) from the original on 12 May 2022. Retrieved 12 May 2022.
- ^ "Voquezna Triple Pak (amoxicillin, clarithromycin, and vonoprazan) FDA Approval History". Drugs.com.
Further reading
- Kajihara Y, Shimoyama T, Mizuki I (February 2017). "Analysis of the cost-effectiveness of using vonoprazan-amoxicillin-clarithromycin triple therapy for first-line Helicobacter pylori eradication". Scand J Gastroenterol. 52 (2): 238–241. doi:10.1080/00365521.2016.1250157. PMID 27806639. S2CID 25801431.
- Nishida T, Tsujii Y, Okamoto A, Tomita R, Higaki Y, Osugi N, et al. (9 July 2019). "A Triple-Drug Blister-Packaged Drug with Vonoprazan Improves First-Line Eradication of Helicobacter pylori in Elderly Patients: A Retrospective Propensity Score-Matched Cohort Study". Digestion. 101 (5): 608–614. doi:10.1159/000501608. PMID 31288235. S2CID 195871882.
- Okubo H, Akiyama J, Kobayakawa M, Kawazoe M, Mishima S, Takasaki Y, et al. (November 2020). "Vonoprazan-based triple therapy is effective for Helicobacter pylori eradication irrespective of clarithromycin susceptibility". J Gastroenterol. 55 (11): 1054–1061. doi:10.1007/s00535-020-01723-6. PMID 32930864. S2CID 221674785.
External links
- "Vonoprazan". Drug Information Portal. U.S. National Library of Medicine.
- "Amoxicillin". Drug Information Portal. U.S. National Library of Medicine.
- "Clarithromycin". Drug Information Portal. U.S. National Library of Medicine.
 | This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it. |